Sartorius Stedim Biotech (LTS:0RG8) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RG8 Sartorius Stedim Biotech SA LTS:0RG8
82 GF Score
Price €166.35
GF Value €200.70
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0RG8
82GF Score
Sartorius Stedim Biotech SA LTS:0RG8
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius Stedim Biotech (LTS:0RG8) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €166.35 is trading 17.1% below its estimated GF Value™ of €200.70. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for LTS:0RG8:

  • Interest Received:
  • GF Value™: €200.70 vs. price of €166.35 (17.1% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the LTS:0RG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for LTS:0RG8

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€166.35
Price
€200.70
GF Value